[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Proton Collaborative Group\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":162},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,69,94,119,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100130619","postoperative-or-salvage-radiotherapy-rt-for-node-negative-prostate-cancer-following-radical-prostatectomy-100130619",false,"NCT00969111","Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy","Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy","Inclusion Criteria:\n\n* Prostate cancer treated primarily with open, laparoscopic or robotically assisted prostatectomy.\n* Maximum PSA value of 20 ng\u002Fml.\n\nExclusion Criteria:\n\n* Evidence of distant metastasis (M1).\n* Prior systemic chemotherapy for any reason.\n* Previous irradiation to the pelvis that would compromise the ability to deliver the prescribed study treatment.\n* Active inflammatory bowel disease (Crohn's disease, diverticulitis or ulcerative colitis) affecting the rectum. (Non-active diverticulitis and Crohn's disease not affecting the rectum are allowed).\n* Prior or concurrent cancer, other than non-melanomatous skin cancer, unless disease free for at least 5 years.\n* Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use during radiation.","MALE","18 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to see what effects, good and\u002For bad, proton radiation, and\u002For conventional radiation and hormonal therapy (if applicable), has on prostate cancer that has already returned or the risk of prostate cancer returning.",[26],"Prostate Cancer",[28],"Proton Radiation, Prostate Cancer","RECRUITING","2026-06-15",{"date":32,"type":33},"2026-06-17","ACTUAL",{"date":35,"type":4},"2009-08",{"date":37,"type":20},"2050-08",{"name":39,"class":40},"Proton Collaborative Group","NETWORK",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100505086","phase-3-conventionally-fractionated-vs-hypofractionated-comprehensive-nodal-irradiation-for-breast-cancer-using-pencil-beam-scanning-proton-therapy-100505086","NCT05856773","Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy","Phase III Randomized Trial of Conventionally Fractionated vs. Hypofractionated COMprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning PROton Therapy (COMPRO)","COMPRO","Inclusion Criteria:\n\n* Patients with Stage I-III breast cancer who have undergone breast conserving surgery or mastectomy and have been recommended to receive postoperative radiation therapy to the breast or chest wall and regional draining lymph nodes (axilla levels I-III, SCV, IMN)\n* Histologically documented breast cancer (invasive mammary, ductal, medullary, tubular, mucinous, lobular, or ductal carcinoma in situ) for which treatment with radiation therapy to the breast\u002Fchest wall and comprehensive regional lymph nodes including the internal mammary chain is recommended\n* Documentation of negative metastatic workup by whole body Positron Emission Tomography - Computed Tomography (PET\u002FCT) or by combined CT of the chest, abdomen, pelvis and Bone scan\n* History and physical exam within 90 days prior to study registration\n* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2\n* Negative pregnancy test for women of child-bearing potential\n* Able to begin radiation treatment within 12 weeks of last surgery or last day of chemotherapy\n* Presence of breast implants, breast expanders, tissue flap, or other breast reconstruction are allowed\n* Bilateral breast cancer is allowed if at least one side will be treated with comprehensive nodal irradiation per protocol treatment and will be recorded as the laterality receiving comprehensive nodal irradiation. If both sides will be treated comprehensively, it will be documented as such\n\nExclusion Criteria:\n\n* Presence of skin ulceration and \u002F or ipsilateral satellite nodules and\u002For edema (including peau d'orange) (T4b or T4c disease) or diagnosis of inflammatory breast cancer (T4d disease)\n* Residual gross disease detected by imaging or clinical exam with the exception of \\\u003C2cm internal mammary lymph node or supraclavicular lymph node amenable to sequential boost\n* Prior history of radiation therapy overlapping with current target volume (including intraoperative brachytherapy, interstitial catheter brachytherapy, balloon brachytherapy, external beam radiation therapy)\n* Prior history of explant surgery or implant removal due to infection or wound healing issues without subsequent implant or flap reconstruction\n* Presence of double\u002Fdual port tissue expander\n* Clinical or radiographic evidence of distant metastatic disease\n* Pregnant or breast-feeding females\n* Non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up\n* History of connective tissue disorder (i.e., systemic lupus erythematosus, scleroderma), dermatomyositis, xeroderma pigmentosum\n* Known BRCA 1 or BRCA 2 mutation\n* Presence of an active skin rash\n* Prior invasive non-study malignancy unless disease free for ≥ 3 years. Non-melanoma skin cancer, well-differentiated thyroid cancers, in situ carcinomas of the oral cavity, cervix, and other organs, and tumors that are not thought to impact the life expectancy of the patient are permissible.","FEMALE","19 Years",{"count":52,"type":20},276,[54],"PHASE3","The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with breast cancer who require radiotherapy to the breast\u002Fchest wall and regional lymph nodes.",[57],"Breast Cancer",[59],"Proton Radiation","2025-09-02",{"date":62,"type":33},"2025-09-09",{"date":64,"type":33},"2024-03-21",{"date":66,"type":20},"2041-02",{"name":39,"class":40},7,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":76,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100255005","phase-2-proton-radiation-for-unresectable-borderline-resectable-or-medically-inoperable-carcinoma-of-the-pancreas-100255005","NCT02598349","Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas","A Phase II Trial of Escalated Dose Proton Radiotherapy With Elective Nodal Irradiation and Concomitant Chemotherapy for Patients With Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Biopsy proven unresectable adenocarcinoma of the pancreas.\n* Have either unresectable, borderline resectable or medically inoperable carcinoma of the pancreas, or refusing surgery.\n* A biliary obstruction is able to participate as long as a drainage tube is in place prior to starting treatment with Proton radiation,\n* Participants of child-producing potential must be willing to use contraception while on treatment and for at least 12 months thereafter.\n* Required pretreatment laboratory parameters:\n\n  * Absolute granulocyte count (AGC\u002FANC) ≥ 1.8 thou\u002Fmm3\n  * Platelet count ≥ 100,000\u002Fmm3\n  * Bilirubin \\\u003C 2 mg\u002Fdl\n  * ALT\u002FSGPT \\\u003C 3x upper limit of normal\n  * Creatinine \\\u003C 3 mg\u002Fdl\n\nExclusion Criteria:\n\n* Evidence of distant metastasis.\n* Prior surgical resection.\n* Previous history of invasive malignancy (except non-melanoma skin cancer and low to intermediate risk prostate cancer) unless the participant has been disease free for 5 years prior to registration.\n* Active or untreated infection,\n* Pregnant or breastfeeding women or subjects of child producing potential not willing to use medically acceptable contraception while on treatment and for at least 12 months thereafter.\n* Previous Radiation to the abdomen.","ALL",{"count":78,"type":20},60,[80],"PHASE2","The prognosis for patients with localized pancreatic adenocarcinoma who are not surgical candidates is poor. Patients characterized as having \"borderline resectable\" disease treated with preoperative chemo-radiotherapy fair somewhat better - although many of these patients are not converted to resectability. It may be argued that intensification of local and regional therapy might 1.) Increase the share of patients able to undergo curative surgery and 2.) Improve the local disease control interval and extend survival for patients who remain unresectable. Therefore, the purpose of this research study is to determine if an increase in the number of surgical resection pancreatic adenocarcinoma is higher than historical data by using a combined treatment of proton radiation with capecitabine (oral chemotherapy).",[83],"Pancreatic Cancer",[85,86],"Unresectable","Borderline resectable",{"date":62,"type":33},{"date":89,"type":4},"2016-04",{"date":91,"type":20},"2040-10",{"name":39,"class":40},4,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":49,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":109,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},"100191324","phase-2-phase-ii-protocol-of-proton-therapy-for-partial-breast-irradiation-in-early-stage-breast-cancer-100191324","NCT01766297","Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer","Inclusion Criteria:\n\n* Must sign study-specific, IRB approved informed consent form prior to study entry. Note consent by legally authorized representative is not allowed for this trial.\n* Must be female.\n* Must be \\> = 50 years of age.\n* Must have a life expectancy of at least 5 years based on age and co-morbidities.\n* Must have pathology proven invasive ductal carcinoma (lobular is not allowed) and\u002For ductal carcinoma in situ (DCIS).\n* One of the following criteria must be met: (a) Tumors that are microscopically multifocal must be 3.0 cm or less in total aggregate size and encompassed within a single scar (b) Patient does not have microscopically multifocal tumor.\n* For tumors that are invasive, if in the presence of extensive intraductal component (EIC), the entire pathologic tumor size (including both the intraductal and invasive component) must be 3.0 cm or less.\n* Must be Stage 0, I, II (Tis, T1, or T2, N0, M0 per AJCC criteria 7th and\u002For 8th Ed.). If stage II, the tumor size must be \\\u003C = 3.0 cm. A patient with invasive histology must have nodal stage pN0 by H\\&E stains on sentinel node biopsy or axillary lymph node dissection.\n* Must have ER positive disease with ER\u002FPR report available.\n* For tumors that are invasive, HER2 must be performed (positive or negative is acceptable).\n* Must have a lumpectomy performed, with documented negative surgical margins by 0.2 cm or more. If re-excision results in negative surgical margins 0.2 cm or more, patient is eligible.\n* If image guidance with daily cone beam CT with direct physician visual assessment is used for treatment positioning, the presence of markers or clips in the surgical bed is recommended but not required. If cone beam CT imaging will NOT be used for image guidance, then the patient must be prepared to have 2 fiducial markers minimum, 3 preferred, placed prior to treatment (if not previously done).\n\n  * If markers or clips were placed at the time of surgery, patient must be able to start treatment within 12 weeks after lumpectomy or re-excision for adequate margins.\n  * If markers were not placed at the time of surgery and are needed, patient must have markers placed within 6 weeks after surgery.\n  * If systemic chemotherapy was given, patient must have had clips or markers placed at the time of surgery (if they are needed) and patient must have simulation scans within 6 weeks of the completion of the chemotherapy.\n* Must be able to start treatment within 12 weeks of surgery or 8 weeks of finalization of chemotherapy.\n\nExclusion Criteria:\n\n* Previous history of ipsilateral invasive breast cancer or DCIS.\n* Any clinical or radiographically suspicious nodes, unless biopsy proven benign.\n* Non-epithelial malignancies such as sarcoma or lymphoma.\n* Suspicious residual microcalcifications on mammography of either breast, unless negative for malignancy on pathology.\n* Multicentric or bilateral disease unless biopsy of the clinical abnormalities are performed and result is negative.\n* Lymphovascular space invasion (LVSI) on pathology specimen.\n* Any previously treated breast carcinoma or synchronous breast carcinoma in ipsilateral breast.\n* Prior radiation therapy to the ipsilateral breast or thorax.\n* Paget's disease of the nipple.\n* Histologic examination showing invasive lobular histology.\n* Skin involvement.\n* Breasts technically unsatisfactory for radiation treatment upon the discretion of the treating physician.\n* Significant infection or other co-existing medical condition that would preclude protocol therapy such as pregnancy, HIV\u002FAIDS or collagen vascular diseases specifically systemic lupus erythematosus, scleroderma, or dermatomyositis.\n* Known BRCA 1 or BRCA 2 mutation.\n* Pregnant or lactating.","50 Years",{"count":102,"type":20},132,[80],"The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy.\n\nThis study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. A clinical study is necessary to compare the results (good or bad) of proton radiation therapy.",[57,106,107,108],"Breast Neoplasm","Breast Tumor","Cancer of the Breast",[57,110,111],"Proton","Radiation",{"date":62,"type":33},{"date":114,"type":4},"2013-02",{"date":116,"type":20},"2035-01",{"name":39,"class":40},9,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":4,"leadSponsor":140,"locationsCount":93},"100170494","phase-3-hypo-fractionated-radiation-therapy-with-or-without-androgen-suppression-for-intermediate-risk-prostate-cancer-100170494","NCT01492972","Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer","Phase III Study of Image Guided Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate","Inclusion Criteria:\n\n* Histologically confirmed prostate adenocarcinoma (within 365 days of randomization) at intermediate risk for reoccurrence determined by at least one of the following: Gleason Score 7, PSA \\> = 10 and \\\u003C = 20, T stage T2b - T2c\n* Clinical stages T1-T2c N0 M0 as staged by the treating investigator. (AJCC Criteria 7th Ed.- appendix III).\n* Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason score must be in the range of 2-7. \\> 6 cores are strongly recommended.\n* PSA values \\\u003C = 20 ng\u002Fml within 90 days prior to randomization. Obtained prior to biopsy or at least 21 days after prostate biopsy.\n* ECOG performance status 0-1 (appendix II) assessed within 90 days of randomization.\n* Patients must sign IRB approved study specific informed consent.\n* Patients must complete all required pre-entry tests listed in section 4.0 within the specified time frames.\n* Patients must be able to start treatment within 56 days of randomization.\n* Patients must be at least 18 years old.\n* For brachytherapy, an IPSS ≤ 21, or ≤ 17 if patient is on medications to improve urination.\n* For brachytherapy, prostate volume must be less than 55cc prior to AS.\n\nExclusion Criteria:\n\n* Pelvic lymph nodes \\> 1.5 cm in greatest dimension unless the enlarged lymph node is biopsied and negative.\n* Previous prostate cancer surgery to include: prostatectomy, hyperthermia and cryosurgery.\n* Previous pelvic radiation for prostate cancer.\n* Previous androgen suppression therapy for prostate cancer.\n* Active rectal diverticulitis, Crohn's disease affecting the rectum or ulcerative colitis (non-active diverticulitis and Crohn's disease not affecting the rectum are allowed).\n* Prior systemic chemotherapy for prostate cancer.\n* History of proximal urethral stricture requiring dilatation.\n* Current and continuing anticoagulation with warfarin sodium (Coumadin), heparin, low- molecular weight heparin, Clopidogrel bisulfate (Plavix), or equivalent (unless it can be stopped to manage treatment related toxicity or to have a biopsy if needed).\n* Major medical, addictive or psychiatric illness which in the investigator's opinion, will prevent the consent process, completion of the treatment and\u002For interfere with follow-up. (Consent by legal authorized representative is not permitted for this study).\n* Evidence of any other cancer within the past 5 years and \\\u003C 50% probability of a 5 year survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell cancer of the skin is allowed).\n* History of myocardial infarction within the last 6 months.",{"count":127,"type":20},192,[54],"The purpose of this study is to compare the effects, good and\u002For bad of two treatment methods on subjects and their cancer.\n\nProton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen suppression is not completely understood. This study will compare the use of hypofraction proton therapy (28 treatments) alone to proton therapy with androgen suppression therapy.",[26],[132,133,134,135],"Prostate","proton","radiation","intermediate risk",{"date":137,"type":33},"2025-09-04",{"date":139,"type":4},"2012-01",{"name":39,"class":40},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":76,"minAge":4,"maxAge":4,"enrollmentInfo":148,"targetDuration":150,"studyType":151,"phases":4,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":4,"leadSponsor":160,"locationsCount":161},"100152403","registry-study-for-radiation-therapy-outcomes-100152403","NCT01255748","Registry Study for Radiation Therapy Outcomes","Evaluation Tracking Project: A Prospective Chart Review of Patients Treated With Radiation Therapy","Inclusion Criteria:\n\n* Planned treatment with radiation therapy\n* Ability to understand and sign IRB approved consent",{"count":149,"type":20},40000,"30 Years","OBSERVATIONAL","The purpose of this research study is to collect and analyze information from patients being treated with various forms of radiation therapy.",[154],"Neoplasms",[156],"cancer, proton, radiation",{"date":62,"type":33},{"date":159,"type":4},"2009-06",{"name":39,"class":40},29,""]